RAS oncogenes: the first 30 years

Cited by (1,002)

Items 601–700 of 1,002

1. Intrinsic GTPase activity of K-RAS monitored by native mass spectrometry
   Moghadamchargari, Zahra, Huddleston, Jamison, Shirzadeh, Mehdi, Zheng, Xueyun, Clemmer, David E., M. Raushel, Frank, Russell, David H., Laganowsky, Arthur · 2019 · Biochemistry
2. Spatial cycles in G‐protein crowd control
   Nachiket Vartak, Philippe I. H. Bastiaens · 2010 · The EMBO Journal
3. Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
   Gang Fan, Shilin Chen, Qingping Zhang, Na Yu, Ziyang Shen, Zhaoji Liu, Weiming Guo, Zhi‐Han Tang, Jing Yang, Miao Liu · 2025 · MedComm
4. Hierarchical scaffolding of an ERK1/2 activation pathway
   Susanne Vetterkind, Ransom H. Poythress, Qian Lin, Kathleen G. Morgan · 2013 · Cell Communication and Signaling
5. Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression
   A. Scholtens, Marnix H. Geukes Foppen, Christian U. Blank, Johannes V. van Thienen, Harm van Tinteren, John B.A.G. Haanen · 2015 · European Journal of Cancer
6. Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy
   Veronica Rainone, Cristina Martelli, Luisa Ottobrini, Mara Biasin, Manuela Borelli, Giovanni Lucignani, Daria Trabattoni, Mario Clerici · 2016 · PLoS ONE
7. Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms
   L-N Fu, Wang Yq, Juan Tan, Jing Xu, Q-Y Gao, YX Chen, J-Y Fang · 2017 · Oncogene
8. Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages
   Dörthe Masemann, Katharina Köther, Meike Kuhlencord, Georg Varga, Johannes Roth, Brian Dennis Lichty, Ulf Rüdiger Rapp, Viktor Wixler, Stephan Ludwig · 2018 · OncoImmunology
9. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS
   Robert Jr. Roskoski · 2021 · Pharmacological Research
10. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer
    Sunny Guin, Dan Theodorescu · 2015 · Acta Pharmacologica Sinica
11. The Chaperone Protein SmgGDS Interacts with Small GTPases Entering the Prenylation Pathway by Recognizing the Last Amino Acid in the CAAX Motif
    Nathan J. Schuld, Jeffrey S. Vervacke, Ellen Lorimer, Nathan C. Simon, Andrew D. Hauser, Joseph T. Barbieri, Mark Dewey Distefano, Carol L. Williams · 2014 · Journal of Biological Chemistry
12. Transcriptional regulation of the interleukin-11 gene by oncogenic Ras
    Soon Young Shin, Chan Choi, H. G. Lee, Young Chang Lim, Young Ho Lee · 2012 · Carcinogenesis
13. Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice
    Feijun Luo, David G. Brooks, Hongtao Ye, Rifat Hamoudi, George Poulogiannis, Charles E. Patek, Douglas J. Winton, Mark Johan Arends · 2007 · Oncogene
14. Farnesylation or geranylgeranylation? Efficient assays for testing protein prenylation in vitro and in vivo
    Wolfgang Benetka, Manfred Koranda, Sebastian Maurer‐Stroh, Fritz Pittner, Frank Eisenhaber · 2006 · BMC Biochemistry
15. Transforming growth factor‐β‐stimulated clone‐22 is a negative‐feedback regulator of Ras / Raf signaling: Implications for tumorigenesis
    Masaki Nakamura, Jiro Kitaura, Yutaka Enomoto, Lu Yang, Koutarou Nishimura, Masamichi Isobe, Katsutoshi Ozaki, Yukiko Komeno, Fumio Nakahara, Toshihiko Oki et al. · 2011 · Cancer Science
16. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy
    Annalisa Savonarola, Raffaele Palmirotta, Fiorella Guadagni, Franco Silvestris · 2012 · The Pharmacogenomics Journal
17. H-Ras Distribution and Signaling in Plasma Membrane Microdomains Are Regulated by Acylation and Deacylation Events
    Lorena Agudo‐Ibáñez, Ana Herrero, Mariano Barbacid, Piero Crespo · 2015 · Molecular and Cellular Biology
18. ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway
    Gejun Zhang, Zi Yu, Shui Fu, Chengcheng Lv, Qingzhuo Dong, Cheng Fu, Chuize Kong, Yu Zeng · 2018 · Cancer Gene Therapy
19. Biochemical diagnostics of pancreatic cancer - Present and future
    Wojciech Jelski, Barbara Mroczko · 2019 · Clinica Chimica Acta
20. Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators
    Yuran Qiu, Yuanhao Wang, Zong‐Tao Chai, Duan Ni, Xinyi Li, Jun Pu, Jie Chen, Jian Zhang, Shaoyong Lu, Chuan Lv et al. · 2021 · Acta Pharmaceutica Sinica B
21. Molecular Biology of Pancreatic Ductal Adenocarcinoma Progression
    Andrew D. Rhim, Ben Z. Stanger · 2010 · Progress in molecular biology and translational science
22. The Ras Effector RASSF2 Controls the PAR-4 Tumor Suppressor
    Howard Donninger, Luke B. Hesson, Michele D. Vos, Kristin E. Beebe, Laura E. Gordon, David Sidransky, Jun Wei Liu, Thomas Schlegel, Shannon R. Payne, Arndt Hartmann et al. · 2010 · Molecular and Cellular Biology
23. Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features
    Keita Harada, Sakiko Hiraoka, J Kato, Arata Horii, Hideyuki Fujita, Kohsaku Sakaguchi, Yasushi Shiratori · 2007 · British Journal of Cancer
24. The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways
    Romain Vasseur, Nicolas Skrypek, Bélinda Duchêne, Florence Renaud, Daniel Martínez‐Maqueda, Audrey Vincent, Nicole Porchet, Isabelle VAN SEUNINGEN, Nicolas Jonckheere · 2015 · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
25. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
    Bruno Vincenzi, Chiara Cremolini, Andrea Sartore Bianchi, Antonio Dello Russo, Francesco Mannavola, Giuseppe Perrone, Francesco Pantano, Fotios Loupakis, Daniele Rossini, Elena Ongaro et al. · 2015 · Oncotarget
26. Promotion of cancer cell stemness by Ras
    Rohan Chippalkatti, Daniel Abankwa · 2021 · Biochemical Society Transactions
27. Drug resistance in targeted cancer therapies with RAF inhibitors
    Ufuk Degirmenci, Jiajun Yap, Yuen Rong M. Sim, Shiru Qin, Jiancheng Hu · 2021 · Cancer Drug Resistance
28. Secondary structure of lipidated Ras bound to a lipid bilayer
    Jörn Güldenhaupt, Yekbun Adıgüzel, Jürgen Kuhlmann, Herbert Waldmann, Carsten Kötting, Klaus Bernhard Gerwert · 2008 · FEBS Journal
29. Protein Prenylation: An (Almost) Comprehensive Overview on Discovery History, Enzymology, and Significance in Physiology and Disease
    Wolfgang Benetka, Manfred Koranda, Frank Eisenhaber · 2006 · Monatshefte für Chemie - Chemical Monthly
30. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice
    Laura K. Zerbe, Lori D. Dwyer‐Nield, Jason M. Fritz, Elizabeth F. Redente, Robert J. Shroyer, Elizabeth Conklin, Shawn Kane, Chris Tucker, S. Gail Eckhardt, Daniel L. Gustafson et al. · 2007 · Cancer Chemotherapy and Pharmacology
31. Molecular Pathogenesis of Sporadic Melanoma and Melanoma-Initiating Cells
    Yunyi Kong, Suresh M. Kumar, Xiaowei Xu · 2010 · Archives of Pathology & Laboratory Medicine
32. Biodegradable nanoparticles as siRNA carriers for in vivo gene silencing and pancreatic cancer therapy
    Guimiao Lin, Chih‐Kuang Chen, Feng Yin, Chengbin Yang, Jinglin Tian, Ting Chen, Gaixia Xu, Chunxiao He, Marie C.M. Lin, Jie Wang et al. · 2017 · Journal of Materials Chemistry B
33. Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer
    Dongmei Zhang, Gao Zhang, Zhongyi Hu, Lawrence Wen Wu, Yi Feng, Sidan He, Youyou Zhang, Zhongyi Hu, Lu Yang, Tian Tian et al. · 2017 · Cancer Research
34. Zinc induces ERK-dependent cell death through a specific Ras isoform
    Claudette Klein, Kimberly M. Creach, Virginia Irintcheva, Katherine J. Hughes, Penny Lane Blackwell, John A. Corbett, Joseph J. Baldassare · 2006 · APOPTOSIS
35. Targeted chemotherapy overcomes drug resistance in melanoma
    Jingyin Yue, Roberto Vendramin, Fan Liu, Omar Lopez, Monica G. Valencia, Helena Gomes Dos Santos, Gabriel Gaidosh, Felipe Beckedorff, Ezra Blumenthal, Lucía Speroni et al. · 2020 · Genes & Development
36. Dasatinib sensitises KRAS -mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity
    Rao, Guanhua, Kim, In-kyu, Conforti, Fabio, Liu, Jing, Zhang, Yu-Wen, Giaccone, Giuseppe · 2018 · European Journal of Cancer
37. Phosphoproteomics Identifies Oncogenic Ras Signaling Targets and Their Involvement in Lung Adenocarcinomas
    Putty‐Reddy Sudhir, Chia‐Lang Hsu, Mei-Jung Wang, Yi-Ting Wang, Yu‐Ju Chen, Ting-Yi Sung, Wen-Lian Hsu, Ueng‐Cheng Yang, Jeou-Yuan Chen · 2011 · PLoS ONE
38. Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors
    Yantao He, Li‐Fan Zeng, Zhi-Hong Yu, Rongjun He, Sijiu Liu, Zhong‐Yin Zhang · 2011 · Bioorganic & Medicinal Chemistry
39. Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal Cancer
    Jérôme Solassol, Julie A. Vendrell, Bruno Märkl, Christian Haas, Beatríz Bellosillo, Clara O. Montagut, Matthew R. Smith, Brendan O’Sullivan, Nicky D’Haene, Marie Le Mercier et al. · 2016 · PLoS ONE
40. Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression
    Michelle Cicchini, Elizabeth L. Buza, Kyra M. Sagal, A. Andrea Gudiel, Amy C. Durham, David M. Feldser · 2017 · Cell Reports
41. Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy
    Yun‐Kai Lin, Fang Zheng, Tianyi Jiang, Zhenghua Wan, Yufei Pan, Yunhan Ma, Yuanyuan Shi, Yexiong Tan, Liwei Dong, Yongjie Zhang et al. · 2018 · Cancer Letters
42. Growth hormone therapy in patients with Noonan syndrome
    Go Hun Seo, Han‐Wook Yoo · 2018 · Annals of Pediatric Endocrinology & Metabolism
43. High ANKZF1 Expression Is Associated With Poor Overall Survival And Recurrence-Free Survival In Colon Cancer
    Xin Zhou, Yanna Shang, Ran Lu, Chuanwen Fan, Xianming Mo · 2019 · Future Oncology
44. The Importance of microRNAs in RAS Oncogenic Activation in Human Cancer
    Roberta Roncarati, Laura Lupini, Ram Charan Shankaraiah, Massimo Negrini · 2019 · Frontiers in Oncology
45. Targeting KRAS in PDAC: A New Way to Cure It?
    Qianyu He, Zuojia Liu, Jin Wang · 2022 · Cancers
46. RAS and PKA pathways in cancer: new insight from transcriptional analysis
    Ferdinando Chiaradonna · 2008 · Frontiers in bioscience
47. The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer
    Slah Ouerhani, Karim Bougatef, Ismael Soltani, Amel Ben Ammar Elgaaïed, Salem Abbès, Samia Menif · 2013 · Molecular Biology Reports
48. Negative regulation of Shh levels by Kras and Fgfr2 during hair follicle development
    Anandaroop Mukhopadhyay, Suguna Rani Krishnaswami, Christopher Cowing-Zitron, Nai‐Jung Hung, Heather Reilly-Rhoten, Julianne E. Burns, Benjamin Yu · 2012 · Developmental Biology
49. Spontaneous nucleotide exchange in low molecular weight GTPases by fluorescently labeled γ-phosphate-linked GTP analogs
    Jonas Korlach, Dan Baird, Ahmed A. Heikal, Kyle R. Gee, Gregory R. Hoffman, Watt W. Webb · 2004 · Proceedings of the National Academy of Sciences
50. Ras and Its Signals Diffuse through the Cell on Randomly Moving Nanoparticles
    Barak Rotblat, Ofer Yizhar, Roni Haklai, Uri Ashery, Yoel Kloog · 2006 · Cancer Research
51. Mitochondrial Ca2+ Remodeling is a Prime Factor in Oncogenic Behavior
    Alessandro Rimessi, Simone Patergnani, Massimo Bonora, Mariusz Roman Wieckowski, Paolo Pinton · 2015 · Frontiers in Oncology
52. Melanoma Mutagenesis and Aberrant Cell Signaling
    Danielle M. Bello, Charlotte Eielson Ariyan, Richard D. Carvajal · 2013 · Cancer Control
53. Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas
    Fresia G. Pareja, Michael S. Toss, Felipe Correa Geyer, Edaise M. da Silva, Mahsa Vahdatinia, Ana Paula Martins Sebastião, Pier Selenica, Austin Szatrowski, Marcia Edelweiss, Hannah Yong Wen et al. · 2019 · Histopathology
54. Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine
    Ling Mei Qian, Kun Chen, Changhong Wang, Zhen Chen, Zhiqiang Meng, Peng Wang · 2020 · Clinical Cancer Research
55. Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification
    Natsuki Osaka, Yoshihisa Hirota, Doshun Ito, Yoshiki Ikeda, Ryo Kamata, Yuki Fujii, Venkat R. Chirasani, Sharon L. Campbell, Koh Takeuchi, Toshiya Senda et al. · 2021 · Frontiers in Molecular Biosciences
56. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer
    Slah Ouerhani, Amel Ben Ammar Elgaaïed · 2012 · Cancer Biomarkers
57. Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells
    Meng Qi Zhao, Hongwei He, Huanxing Sun, Kaihuan Ren, Rong‐Guang Shao · 2009 · Biochemical and Biophysical Research Communications
58. Protein Kinase Cδ Is a Therapeutic Target in Malignant Melanoma with NRAS Mutation
    Asami Takashima, Brandon English, Zhihong Chen, Juxiang Cao, Rutao Cui, Robert M. Williams, Douglas V. Faller · 2014 · ACS Chemical Biology
59. Targeting Raf/MEK/ERK pathway in pituitary adenomas
    Suojun Zhang, Wan Feng, Guo Dongsheng, Ting Lei · 2011 · European Journal of Cancer
60. MicelackingRas- GRF1 showcontextualfearcondition- ing butnotspatialmemoryimpair- ments:convergentevidencefromtwo independentlygeneratedmousemutant lines
    Raffaele d’Isa · 2011 · Frontiers in Behavioral Neuroscience
61. Combined Delivery of Let-7b MicroRNA and Paclitaxel via Biodegradable Nanoassemblies for the Treatment of KRAS Mutant Cancer
    Xin Dai, Wei Qiang Fan, Yingzhe Wang, Lijie Huang, Ying Jiang, Lei Shi, DeAngelo Mckinley, Wen Tan, Chalet Tan · 2015 · Molecular Pharmaceutics
62. Knock-in of Oncogenic Kras Does Not Transform Mouse Somatic Cells But Triggers a Transcriptional Response that Classifies Human Cancers
    Sabrina Arena, Claudio Isella, Miriam Martini, Ario de Marco, Enzo Médico, Alberto Bardelli · 2007 · Cancer Research
63. Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design
    Chen, Long, Zhuang, Chunlin, Lu, Junjie, Jiang, Yan, Sheng, Chunquan · 2018 · Journal of Medicinal Chemistry
64. Molecular Complexity of Colorectal Cancer: Pathways, Biomarkers, and Therapeutic Strategies
    Zhengdong Yang, Xinyang Wang, Huiying Zhou, Minghan Jiang, Jinghui Wang, Bowen Sui · 2024 · Cancer Management and Research
65. Building high-resolution synthetic lethal networks: a ‘Google map’ of the cancer cell
    James Paul, Shaina D'Lee Templeton, Akanksha Baharani, Andrew Freywald, Franco J. Vizeacoumar · 2014 · Trends in Molecular Medicine
66. Prediction in the face of uncertainty: A Monte Carlo-based approach for systems biology of cancer treatment
    Christoph Wierling, Alexander Kühn, Hendrik Hache, Andriani Daskalaki, Elisabeth Maschke-Dutz, Svetlana Peycheva, Jian Li, Ralf Herwig, Hans Rudolf Lehrach · 2012 · Mutation Research/Genetic Toxicology and Environmental Mutagenesis
67. Impact of KRAS Mutations on Management of Colorectal Carcinoma
    Kevin M. Sullivan, Peter S. Kozuch · 2011 · Pathology Research International
68. PUF-8 negatively regulates RAS/MAPK signalling to promote differentiation of C. elegans germ cells
    Samir Vaid, Mohd Ariz, Amaresh Chaturbedi, Ganga Anil Kumar, Kuppuswamy Subramaniam · 2013 · Development
69. Rasopathies: Developmental Disorders That Predispose to Cancer and Skin Manifestations
    Angela Hernández‐Martín, Antonio Torrelo · 2011 · Actas Dermo-Sifiliográficas
70. New ligation independent cloning vectors for expression of recombinant proteins with a self-cleaving CPD/6xHis-tag
    Marco Biancucci, Jazel S. Dolores, Jennifer Wong-Roushar, S. Grimshaw, W.F. Anderson, K.J.F. Satchell, Keehwan Kwon · 2017 · BMC Biotechnology
71. Current knowledge of risk factors for testicular germ cell tumors
    Tomoya Fukawa, Hiro‐omi Kanayama · 2018 · International Journal of Urology
72. Association of KRAS and NRAS gene polymorphisms with Wilms tumor risk: a four-center case-control study
    Wen Fu, Zhenjian Zhuo, Rui‐Xi Hua, Kai Fu, Wei Jia, Jinhong Zhu, Jiao Zhang, Jiwen Cheng, Haixia Zhou, Huimin Xia et al. · 2019 · Aging
73. New Noonan Syndrome Model Mice with RIT1 Mutation Exhibit Cardiac Hypertrophy and Susceptibility to β-adrenergic Stimulation-Induced Cardiac Fibrosis
    Shingo Takahara, Shinichi Inoue, Sachiko Miyagawa‐Tomita, Katsuhisa Matsuura, Yasumi Nakashima, Tetsuya Niihori, Yoichi Matsubara, Yoshikatsu Saiki, Yoko Aoki · 2018 · EBioMedicine
74. RAS-associated Autoimmune Leukoproliferative disease (RALD) manifested with early-onset SLE-like syndrome: a case series of RALD in Chinese children
    Wei Wang, Yu Ling Zhou, Linqing Zhong, Lin Wang, Xiaoyan Tang, Mingsheng Ma, Ji Li, Hongmei Song · 2019 · Pediatric Rheumatology
75. RAS pathway regulation in melanoma
    Amira Al Mahi, Julien Ablain · 2022 · Disease Models & Mechanisms
76. Characterization of a novel KRAS mutation identified in Noonan syndrome
    Abdur M. Razzaque, Yuta Komoike, Tsutomu Nishizawa, Kei Inai, Michiko Furutani, Toru Higashinakagawa, Rumiko Matsuoka · 2012 · American Journal of Medical Genetics Part A
77. The C-Terminus of H-Ras as a Target for the Covalent Binding of Reactive Compounds Modulating Ras-Dependent Pathways
    Clara L. Oeste, Beatriz Díez-Dacal, Francesca Bray, Mario Garcı́a de Lacoba, Beatriz G. de la Torre, David Andreu, Antonio J. Ruiz-Sánchez, Ezequiel Pérez‐Inestrosa, Carlota A. García-Domínguez, José M. Rojas et al. · 2011 · PLoS ONE
78. NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation
    Ann‐Kathrin Eisfeld, Sebastian Schwind, Kevin W. Hoag, Christopher James Walker, Sandya Liyanarachchi, Ravi K. Patel, Xiaomeng Huang, Joseph Markowitz, Wenrui Duan, Gregory A. Otterson et al. · 2014 · Proceedings of the National Academy of Sciences
79. bHLH-zip Transcription Factor Spz1 Mediates Mitogen-Activated Protein Kinase Cell Proliferation, Transformation, and Tumorigenesis
    Shih‐Hsien Hsu, Hsiu-Mei Hsieh-Li, Hsin‐Yi Huang, Pei‐Hsin Huang, Hung Li · 2005 · Cancer Research
80. Sprouty-related Ena/Vasodilator-stimulated Phosphoprotein Homology 1-Domain-containing Protein (SPRED1), a Tyrosine-Protein Phosphatase Non-receptor Type 11 (SHP2) Substrate in the Ras/Extracellular Signal-regulated Kinase (ERK) Pathway
    Martina Quintanar‐Audelo, Permeen Yusoff, Saravanan Sinniah, Sumana Chandramouli, Graeme R. Guy · 2011 · Journal of Biological Chemistry
81. The awakening of an advanced malignant cancer: An insult to the mitochondrial genome
    Cody C. Cook, Masahiro Higuchi · 2011 · Biochimica et Biophysica Acta (BBA) - General Subjects
82. Targeted cancer therapies
    Eleni A. Georgakopoulou, Justin Stebbing, Crispian M. Scully · 2018 · The Journal of the American Dental Association
83. Structural Biology-Inspired Discovery of Novel KRAS–PDEδ Inhibitors
    Jiang, Yan, Zhuang, Chunlin, Chen, Long, Lu, Junjie, Dong, Guoqiang, Miao, Zhenyuan, Zhang, Wannian, Li, Jian, Sheng, Chunquan · 2017 · Journal of Medicinal Chemistry
84. KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
    Nastaran Karimi, Seyed Javad Moghaddam · 2023 · Cells
85. Therapeutic potential of siRNA and DNAzymes in cancer
    Hanuma Kumar Karnati, Ravi Shekar Yalagala, Ram Babu Undi, Satya Ratan Pasupuleti, Ravi Kumar Gutti · 2014 · Tumor Biology
86. Current therapy of advanced colorectal cancer according to RAS/RAF mutational status
    Gábor Lakatos, Claus‐Henning Köhne, Gyorgy Bodoky · 2020 · Cancer and Metastasis Reviews
87. Ras, PI3K and mTORC2 – three's a crowd?
    Stephen F. Smith, Shannon E. Collins, Pascale G. Charest · 2020 · Journal of Cell Science
88. Bayesian nonlinear model selection for gene regulatory networks
    Yang Ni, Francesco C. Stingo, Veerabhadran Baladandayuthapani · 2015 · Biometrics
89. Ras Triggers Ataxia-telangiectasia-mutated and Rad-3-related Activation and Apoptosis through Sustained Mitogenic Signaling
    Aphrothiti J. Fikaris, Aurélia E. Lewis, Adili Abulaiti, Oxana M. Tsygankova, Judy L. Meinkoth · 2006 · Journal of Biological Chemistry
90. A Pan-GTPase Inhibitor as a Molecular Probe
    Lin Hong, Yuna Guo, Soumik BasuRay, Jacob Ongudi Agola, Elsa Romero, Denise S. Simpson, Chad E. Schroeder, Peter C. Simons, Anna Waller, Matthew J. Garcia et al. · 2015 · PLoS ONE
91. Overview of simulation studies on the enzymatic activity and conformational dynamics of the GTPase Ras
    Priyanka Prakash, Alemayehu Abebe Gorfe · 2014 · Molecular Simulation
92. Novel therapeutic target for cancer stem cells in hepatocellular carcinoma
    Hiroaki Nagano, Hideshi Ishii, Shigeru Marubashi, Naotsugu Haraguchi, Hidetoshi Eguchi, Yuichiro� Doki, Masaki Mori · 2012 · Journal of Hepato-Biliary-Pancreatic Sciences
93. Translation‐dependent mechanisms lead to PML upregulation and mediate oncogenic K‐RAS‐induced cellular senescence
    Pier Paolo Scaglioni, Andrea Rabellino, Thomas M. Yung, Rosa Bernardi, Sooyeon Choi, Georgia Konstantinidou, Caterina Nardella, Ke Cheng, Pier Paolo Pandolfi · 2012 · EMBO Molecular Medicine
94. Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK
    Peter Kubiniok, Hugo Lavoie, Marc Therrien, Pierre Thibault · 2017 · Molecular & Cellular Proteomics
95. Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy
    Vikas Jhawat, Monika Gulia, Sumeet Gupta, Balaji Maddiboyina, Rohit Dutt · 2020 · Journal of Controlled Release
96. The Level of Preoperative Plasma KRAS Mutations and CEA Predict Survival of Patients Undergoing Surgery for Colorectal Cancer Liver Metastases
    Jiří Polívka, Jindra Windrichová, Martin Pešta, Kateřina Houfková, Hana Řezáčková, Tereza Macanova, Ondřej Vyčítal, Radek Kučera, David Slouka, Ondřej Topolčan · 2020 · Cancers
97. Chemical-based risk assessment and in vitro models of human health effects induced by organic pollutants in soils from the Olona valley
    Diego Baderna, Andrea Colombo, Giorgia Amodei, Stefano Cantù, Federico Teoldi, Felice Cambria, Giuseppe Rotella, Fabrizio Natolino, Marco Lodi, Emilio Benfenati · 2013 · The Science of The Total Environment
98. Therapeutic opportunities to control tumor cell cycles
    Marcos Malumbres · 2006 · Clinical & Translational Oncology
99. Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach
    Mark P. LeGolvan, Ross Taliano, Murray B. Resnick · 2012 · Human Pathology
100. KRAS mutations: Analytical considerations
     Marta Herreros‐Villanueva, Chih-Chieh Chen, Shyng‐Shiou F. Yuan, Ta‐Chih Liu, Tze‐Kiong Er · 2014 · Clinica Chimica Acta